مباشر

FierceBiotechGilead loosens ties to Arcus after TIGIT dream finally ends in phase 3 failure FierceBiotechWith $50M from Flagship Pioneering, Serif strives to write new chapter for DNA medicines Lonza NewsFDA-backed drug project tests modeling to reduce some human studies - Stock Titan Thermo FisherSaladax Biomedical and Thermo Fisher Scientific Partner on Global Distribution of Drug Monitoring Assays - Clinical Lab Products Thermo FisherTD Cowen Lowers Thermo Fisher (TMO) Price Target, Keeps Buy Rating - Yahoo Finance Lonza NewsLonza Group AG stock (CH0013841017): Is its biopharma contract model resilient enough for new growth - AD HOC NEWS FierceBiotechReplimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection 10x Genomics Blog10x Genomics debuts Atera, a new platform to redefine how biology is measured and understood at AACR 2026 - SelectScience IlluminaClinical Genomic Market: Growth and Outlook Driven by Illumina, - openPR.com Thermo FisherAssessing Thermo Fisher Scientific (TMO) Valuation After New PCR Launch And Data Partnerships - simplywall.st Curiosis Inc.Working capital per share of Curiosis, Inc. – KRX:494120 - TradingView WatersWaters Corporation Schedules First Quarter 2026 Earnings Conference Call - ChartMill

Cell ٢٥ نوفمبر ٢٠٢٥

Reprogramming of microspore fate via <em>BBM</em>-<em>BAR1</em> for highly efficient <em>in vivo</em> haploid induction

Publication date: 30 October 2025Source: Cell, Volume 188, Issue 22Author(s): Ce Shi, Zifu Zhao, Yicheng Zhong, Ying Qiao, Lai Zhang, Fan Yang, Siyuan Li, Lulu...

Publication date: 30 October 2025Source: Cell, Volume 188, Issue 22Author(s): Ce Shi, Zifu Zhao, Yicheng Zhong, Ying Qiao, Lai Zhang, Fan Yang, Siyuan Li, Lulu Li, Lanjie Huang, Xingchun Tang, Pan Luo, Meng-Xiang Sun